Read beyond «well tolerated»
Six historical oral or intravenous AOD-9604 trials summarized in one article.
What did they want to find out?
What problems were recorded and which routes were studied?
What did researchers observe?
The overall account is favorable, but its body includes a possibly related serious event.
What does this mean for you?
Safety depends on formulation, route, duration and reporting quality; «not definitely related» does not mean «risk-free».
What we still do not know
This validates neither injecting it under the skin nor the quality of vial contents.
Show study details
Original sources checked on 4 October 2026. AI-assisted editorial summaries, not a systematic review or an independent medical assessment.
Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans
Journal of Endocrinology and Metabolism · 2013
How it was studied
One safety report combining six randomized, double-blind, placebo-controlled trials; oral and intravenous routes.. Approximately 900 participants across six trials according to the article; maximum treatment duration 24 weeks..
Study finding
The report describes tolerability generally similar to placebo. METAOD003 describes serious diarrhea as possibly related, despite the abstract's general assertion.
Study limitations
An internal discrepancy, not proof of causation. Subcutaneous administration and current vials were not studied; a safety report does not establish weight loss.
Who is behind the study?
- Identified authors
- Heike Stier, Evert Vos, David Kenley
- Funding and involvement
- Metabolic Pharmaceuticals funded all six trials.
- Disclosed interests and verification limits
- Kenley disclosed a 6.9% interest in Calzada, owner of Metabolic Pharmaceuticals; Vos was a consultant and former medical director. Stier's employer consulted for the sponsor.
Terms explained
- Possibly related
- An event might be linked to the intervention, but causation was not established.
- Intravenous route
- Administration into a vein; not the same as under the skin.
Read the source and its limitations. A reference does not automatically validate a commercial product.
Read the source